Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2016

Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2016
Published Jul 30, 2016
75 pages — Published Jul 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2016, provides in depth analysis on Transforming Growth Factor Beta 1 (TGFB1) targeted pipeline therapeutics.

The report provides comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)
- The report reviews Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 1 (TGFB1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Devel

  
Source:
Document ID
GMDHC0443TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Transforming Growth Factor Beta 1 (TGFB1) Overview81
Therapeutics Development94
  Transforming Growth Factor Beta 1 (TGFB1) Products under Development by Stage of Development91
  Transforming Growth Factor Beta 1 (TGFB1) Products under Development by Therapy Area101
  Transforming Growth Factor Beta 1 (TGFB1) Products under Development by Indication112
Transforming Growth Factor Beta 1 (TGFB1) Pipeline Products Glance132
  Late Stage Products131
  Early Stage Products141
Transforming Growth Factor Beta 1 (TGFB1) Products under Development by Companies152
Transforming Growth Factor Beta 1 (TGFB1) Products under Development by Universities/Institutes172
Transforming Growth Factor Beta 1 (TGFB1) Therapeutics Assessment196
  Assessment by Monotherapy/Combination Products191
  Assessment by Mechanism of Action201
  Assessment by Route of Administration212
  Assessment by Molecule Type232
Transforming Growth Factor Beta 1 (TGFB1) Companies Involved in Therapeutics Development2512
  Acceleron Pharma, Inc.251
  Digna Biotech, S.L.261
  Dong Wha Pharma Co., Ltd.271
  Eli Lilly and Company281
  Huabo Biopharm Co., Ltd.291
  Isarna Therapeutics GmbH301
  Johnson &Johnson311
  Novartis AG321
  Scholar Rock, Inc.331
  Sirnaomics, Inc.341
  Taisho Pharmaceutical Holdings Co., Ltd.351
  TissueGene, Inc.361
Transforming Growth Factor Beta 1 (TGFB1) Drug Profiles3723
  ACE-1332 Drug Profile371
  Antibody to Inhibit TGF-Beta 1 for Osteoarthritis Drug Profile381
  Antibody to Inhibit TGFB1 for Oncology Drug Profile391
  decorin Drug Profile401
  disitertide Drug Profile412
  DW-1029M Drug Profile431
  HB-001 Drug Profile441
  HB-002 Drug Profile451
  ISTH-1047 Drug Profile461
  ISTH-1106 Drug Profile471
  melittin Drug Profile481
  Monoclonal Antibodies to Inhibit TGF Beta 1 for Fibrosis Drug Profile491
  Monoclonal Antibody to Activate TGF beta1 for Autoimmune Disorders Drug Profile501
  Monoclonal Antibody to Inhibit TGF Beta1 for Oncology Drug Profile511
  Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain Drug Profile521
  STP-705 Drug Profile532
  TASP-0382088 Drug Profile551
  tonogenchoncel-L Drug Profile563
  XOMA-089 Drug Profile591
Transforming Growth Factor Beta 1 (TGFB1) Dormant Projects603
Transforming Growth Factor Beta 1 (TGFB1) Discontinued Products631
Transforming Growth Factor Beta 1 (TGFB1) Featured News &Press Releases6410
  Feb 16, 2016: Regenerative Medicine Company, TissueGene, adds Dr. Gurdyal Kalsi as Chief Medical Officer641
  Jul 14, 2015: Scholar Rock Presents Preclinical Data for First Demonstration of Novel Pharmacological Approach to Targeting the TGF 1 Latent Complex641
  May 11, 2015: TissueGene Presents Phase 2 Data for Its Novel Cell Therapy for the Treatment of Osteoarthritis of the Knee651
  Jan 22, 2015: Sirnaomics Files to Begin Trial of Scar-healing Drug in China as it Seeks Funding in US652
  Jan 05, 2015: Sirnaomics and Partner Submit IND to CFDA671
  Nov 17, 2014: TissueGene Receives Recommendations from FDA on Pathway to Phase 3 Trial of TG-C for Treatment of Osteoarthritis of the Knee681
  Nov 14, 2012: TissueGene Completes Enrollment In US Phase II Study Of TG-C In Patients With Knee Osteoarthritis681
  Jun 28, 2012: Sirnaomics Nears Phase I Study of Wound-Healing Drug as It Eyes the microRNA Field682
  Jun 25, 2012: Sirnaomics Receives NIH SBIR Grant For Developing siRNA Therapeutic Product STP705701
  May 19, 2011: TissueGene Initiates Patient Enrollment For Phase II Study Of TG-C For Osteoarthritis Of Knee701
  Mar 25, 2010: Digna Biotech Announced The Results Of Disitertide Proof Of Concept Trial In The Topical Treatment Of Skin Fibrosis711
  Mar 03, 2009: TissueGene Announces Regulatory Allowance To Initiate Phase IIa Study Of TG-C In South Korea For Osteoarthritis Of The Knee711
  Oct 19, 2007: Digna Biotech Biotechnological Company and Isdin Laboratory Begin Phase II Of A Product For Scleroderma721
  Jul 24, 2006: TissueGene Initiates Phase I Clinical Trial with TG-C721
  Apr 19, 2005: RheoGene Inc. And TissueGene Inc. Sign Collaborative Agreement For Bone Regeneration And Repair Program722
Appendix742
  Methodology741
  Coverage741
  Secondary Research741
  Primary Research741
  Expert Panel Validation741
  Contact Us741
  Disclaimer751

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2016" Jul 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Transforming-Growth-Factor-Beta-1-TGFB1-Pipeline-Review-H2-2016-2088-16340>
  
APA:
Global Markets Direct - Market Research. (2016). Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2016 Jul 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Transforming-Growth-Factor-Beta-1-TGFB1-Pipeline-Review-H2-2016-2088-16340>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.